Curevac launches the construction of new GMP-compliant RNA production plant

CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of RNA-based drugs, announced the groundbreaking of its industrial-scale, GMP-compliant production facility at its headquarters in Tübingen, Germany.

The novel production facility – called GMP IV – will be able to produce approximately 30 million doses of RNA-based therapeutics per year, and is expected to be fully commissioned in 2019.

Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, stated, “I am thrilled to celebrate the construction of our new building together with our partners and long-standing investor, Dietmar Hopp. With this new manufacturing facility, we will meet the future demands of our growing clinical programs and initial requirements for product commercialization. We will also be well prepared for the needs of our partners’ programs, including our newly established collaboration with Lilly.”

GMP IV has a usable floor space of 8,800 square meters which is designed to give CureVac flexibility in producing a wide variety of RNA-based products. CureVac also has the ability to expand the building to fulfill future market needs for its RNA products. Recently, CureVac completed the development of its third in-house suite, GMP III. This suite is designed to operate under a newly developed and patent-protected process optimized for large-scale production. Manufacturing of RNA products in this facility will begin in 2018.

Since 2006, CureVac has operated the first worldwide GMP-compliant RNA production plant with two multi-product suites – GMP I and GMP II – for large RNA molecules for use in medical applications against cancer, infectious diseases and other illnesses.

SOURCE: curevac
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.